Navigation Links
TessArae Delivers Lower Cost Option to Genetic Testing Market
Date:11/9/2009

POTOMAC FALLS, Va., Nov. 9 /PRNewswire/ -- TessArae® LLC, a global leader in resequencing microarray-based applications, announces the launch of new integrated product solutions for genetic testing of the mutations that underlie human hereditary diseases. The combination of TessArae's expertise in microarray-based resequencing with novel nucleotide sequence basecalling algorithms and analysis software enables screening for all targeted mutations in multiple genes of a syndrome or disorder simultaneously. This dramatically reduces total testing cost and time-to-result without compromising test accuracy and usability for providers of genetic testing services. The first solution, offered by GeneDx (Gaithersburg, MD), is for Noonan Syndrome, a genetic disorder that causes abnormal development of multiple parts of the body. "Implementation of the custom-designed resequencing solution from TessArae, which simultaneously detects all known mutations and screens for missense mutations in eight genes of the RAS/MAPK pathway, allows GeneDx to offer a more comprehensive test than we could previously, yet at significantly lower cost and with much faster turnaround time," states John Compton, Ph.D., Co-President and Scientific Director of GeneDx. "Based on the successful integration of this technology into our laboratory workflow, we plan to offer TessArae-developed resequencing microarray-based testing for Periodic Fever Syndromes in the immediate future." According to Klaus Schafer, M.D., MPH, President and CEO of TessArae, "The human genetic disease testing market represents a new opportunity for us. Our resequencing microarray-based solution is ideally positioned, from both a cost and time-to-result perspective, between conventional and next-gen DNA sequencing technologies, and will generate significant revenue as the genetic testing market grows."

About TessArae: TessArae's TessArray® RPM (Resequencing Pathogen Microarray) technology simultaneously detects and identifies numerous viral, bacterial, and fungal pathogens, from clinical, environmental and product samples, enabling characterization -- to the strain level -- all in a same-day, single-sample, multiple-result test. TessArae's technology is the only multiplexed genotypic technology that provides direct nucleotide sequence information from pathogen-specific genomic signatures. TessArae has several commercially available products for Research Use Only purposes, including the RPM-Flu Kit for detection and definitive identification of respiratory pathogens, the RPM-TEI Kit for tropical and emerging infections, and the RPM-HFV Kit for whole genome resequencing of HFV hemorrhagic fever viruses. TessArae is based in Potomac Falls, Loudoun County, VA just outside Washington, DC. TessArae products are not intended for in vitro diagnostic use or for patient treatment decisions.

SOURCE TessArae, LLC


'/>"/>
SOURCE TessArae, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
2. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
3. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
4. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
5. Vtech(R) Delivers Todays Hottest Trends to Tech-Savvy Kids
6. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
7. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
8. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
9. Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children
10. Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75
11. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):